NR3C1 KO VSTs persist in vivo even after treatment with dexamethasone. (A) Schematic diagram representing the timeline for the in vivo experiments. NSG mice received 1 dose (1 × 106) of control Cas9 or NR3C1 KO VSTs and were either observed (top panel) or treated with a daily subcutaneous dose of dexamethasone (15 mg/kg) for 2 weeks (bottom panel) (n = 5 mice per group). (B) All mice were euthanized on day +14 after the adoptive infusion of Cas9 control or NR3C1 KO VSTs. Cells were collected from the bone marrow and analyzed by flow cytometry for the expression of human CD45 (hCD45) and CD3. Representative FACS plots are presented. Inset values indicate the percentage of CD3+ cells from each group. (C) Bar graph shows the pooled data for the percentage of CD3+ cells from panel B (n = 5). The bars represent mean values with SD. The statistical significance is indicated as *P ≤ .05.